4D-therapy
Financiado
Multimodal “4D”-therapy of pediatric high grade glioma
Paediatric high grade glioma (pHGG) is the most common malignant childhood brain tumour with standard-of-care inevitably resulting in therapy-resistant relapse or disease progression. The need for new combinatorial treatments is u...
Paediatric high grade glioma (pHGG) is the most common malignant childhood brain tumour with standard-of-care inevitably resulting in therapy-resistant relapse or disease progression. The need for new combinatorial treatments is universally acknowledged; however, modern combination therapies are sparse, include at most two modalities and have so far not been able to significantly improve the dismal prognosis of the disease.In this proposal, I conceptualize a highly targeted multimodal treatment strategy for pHGG (4D-therapy) based on complementary precision medicine approaches. The system leverages multiple inter-modal synergies, overcomes resistance to individual therapies and disperses off-targeting to different cell populations, thereby creating a large therapeutic window.Initially, we will conduct a comprehensive screen to evaluate a novel regimen of combined upfront targeted drug- and radiotherapy (RT), followed by functional validation in vitro and in vivo. In-depth molecular profiling will allow us to unravel mechanisms of radiosensitization.Further, we aim to establish an innovative gene therapy approach with unprecedented, highly specific tropism for tumour cells by combining elaborately selected adeno-associated viruses and nanocapsules with newly identified Cas-nucleases.Ultimately, we will systematically combine drug-RTs, gene therapies and existing tumour-specific CAR-T cells within a rationally designed, multimodal treatment regimen and evaluate its efficacy in a series of preclinical studies. A broad representation of patient-derived xenografts, complemented by immunocompetent allograft models will provide leading-edge predictive power and a unique dataset to investigate multimodal interactions.I expect this project to provide pioneering insights into inter-modal treatment synergies, to produce stratified treatment protocols for pHGG, directly informing clinical trials and to become a pathbreaking feasibility study for multimodal cancer therapy.
ver más
Duración del proyecto: 59 meses
Fecha Inicio: 2024-01-01
Fecha Fin: 2028-12-31
Fecha Fin: 2028-12-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-01-01
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2023-STG:
ERC STARTING GRANTS
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
1M€
Líder del proyecto
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5